Grants and Contracts Details
Description
HUMAN CLINICAL TRIAL - CONFIDENTIAL
COG Protocol AAML1031 entitled, “A Phase III Randomized Trial for Patients with de novo AML
using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High
Allelic Ratio FLT3/ITD”.
SUBCONTRACTE shall carry out the clinical trial research study set forth in the
research protocol COG Protocol AAML1031 entitled, “A Phase III Randomized Trial for Patients with de
novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for
Patients with High Allelic Ratio FLT3/ITD”
Status | Active |
---|---|
Effective start/end date | 3/31/17 → 5/2/25 |
Funding
- Public Health Institute: $363.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.